Eldecalcitol

Analog of 1,25-dihydroxyvitamin D3 CAS# 104121-92-8

Eldecalcitol

Catalog No. BCC1548----Order now to get a substantial discount!

Product Name & Size Price Stock
Eldecalcitol: 5mg $10925 In Stock
Eldecalcitol: 10mg Please Inquire In Stock
Eldecalcitol: 20mg Please Inquire Please Inquire
Eldecalcitol: 50mg Please Inquire Please Inquire
Eldecalcitol: 100mg Please Inquire Please Inquire
Eldecalcitol: 200mg Please Inquire Please Inquire
Eldecalcitol: 500mg Please Inquire Please Inquire
Eldecalcitol: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Eldecalcitol

Number of papers citing our products

Chemical structure

Eldecalcitol

3D structure

Chemical Properties of Eldecalcitol

Cas No. 104121-92-8 SDF Download SDF
PubChem ID 6438982 Appearance Powder
Formula C30H50O5 M.Wt 490.72
Type of Compound N/A Storage Desiccate at -20°C
Synonyms ED-71; 1,25-dihydroxyvitamin D3
Solubility Soluble in DMSO
Chemical Name (1S,2S,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol
SMILES CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(C(C(C3=C)O)OCCCO)O)C
Standard InChIKey FZEXGDDBXLBRTD-SJSKTVLPSA-N
Standard InChI InChI=1S/C30H50O5/c1-20(9-6-15-29(3,4)34)24-13-14-25-22(10-7-16-30(24,25)5)11-12-23-19-26(32)28(27(33)21(23)2)35-18-8-17-31/h11-12,20,24-28,31-34H,2,6-10,13-19H2,1,3-5H3/b22-11+,23-12-/t20-,24-,25+,26+,27+,28+,30-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Eldecalcitol

DescriptionEldecalcitol is an analog of the active form of vitamin D3.
Targetsosteoporosis    

Eldecalcitol Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Eldecalcitol Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Eldecalcitol

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.0378 mL 10.1891 mL 20.3782 mL 40.7564 mL 50.9455 mL
5 mM 0.4076 mL 2.0378 mL 4.0756 mL 8.1513 mL 10.1891 mL
10 mM 0.2038 mL 1.0189 mL 2.0378 mL 4.0756 mL 5.0946 mL
50 mM 0.0408 mL 0.2038 mL 0.4076 mL 0.8151 mL 1.0189 mL
100 mM 0.0204 mL 0.1019 mL 0.2038 mL 0.4076 mL 0.5095 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Eldecalcitol

Osteoporosis is characterized by a reduction in bone mass with age, contributing to a loss in bone strength. Vitamin D is a crucial factor for the intestinal absorption of calcium to maintain bone strength. 1α,25(OH)2D3 and its prodrugs alfacalcidol (ALF) and eldecalcitol are widely used in the treatment of Ca- and bone-related diseases including osteoporosis, hyperparathyroidism, osteomalacia, and renal osteodystrophy.

In vitro: Compared with 1α,25(OH)2D3, eldecalcitol has a higher affinity for serum DBP, binds more weakly to VDR, and shows lower potency in suppression of serum PTH. Moreover, the plasma half-life of eldecalcitol is longer than that of 1α,25(OH)2D3, probably due to the higher affinity for DBP [1].

In vivo: In ovariectomized rat model of osteoporosis, eldecalcitol was found to have a greater activity than alfacalcidol in suppressing bone resorption as well as increasing bone mineral density (BMD) [2].

Clinical trial: Eldecalcitol is approved in Japan for the treatment of osteoporosis. Compared to a placebo treatment, treatment with eldecalcitol for 1 year significantly increased lumbar spine and total hip bone mineral density (BMD) and reduced bone turnover markers in a dose-dependent manner [3].

Reference:
[1] Noguchi Y, Kawate H, Nomura M, Takayanagi R.  Eldecalcitol for the treatment of osteoporosis. Clin Interv Aging. 2013;8:1313-21.
[2] Sakai S, Endo K, Takeda S, Mihara M, Shiraishi A.  Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength. Bone. 2012 May;50(5):1054-63.
[3] Shiraki M, Saito H, Matsumoto T.  Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels. Curr Med Res Opin. 2012 Sep;28(9):1547-52.

Featured Products
New Products
 

References on Eldecalcitol

Combined use of ibandronate and eldecalcitol in postmenopausal Japanese women with osteoporosis.[Pubmed:28031507]

J Orthop Surg (Hong Kong). 2016 Dec;24(3):362-366.

PURPOSE: To evaluate the effect of combined use of ibandronate and Eldecalcitol for 6 to 12 months on bone mineral density (BMD) and bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis. METHODS: BMD and bone strength of the proximal femur were evaluated in 78 postmenopausal women (mean age, 73.6 years) who underwent treatment for osteoporosis with combined use of ibandronate and Eldecalcitol for at least 6 months. BMD was measured at the lumbar spine, femoral neck, and total hip using dual-energy X-ray absorptiometry (DXA) at baseline and every 6 months thereafter. Hip structure analysis of the narrow neck and intertrochanter was performed by a radiologist using DXA images. RESULTS: Respectively for the lumbar spine, femoral neck, and total hip, BMD significantly increased (from baseline) by 4.54%, 2.31%, and 1.56% at 6 months and by 5.92%, 3.02%, and 2.70% at 12 months. In hip structure analysis, most parameters improved significantly. Respectively for the narrow neck and intertrochanter, BMD significantly increased (from baseline) by 2.37% and 2.71% at 6 months and by 3.46% and 3.52% at 12 months; cross-sectional area significantly increased by 1.83% and 3.39% at 6 months and by 2.91% and 3.46% at 12 months; section modulus significantly increased by 2.42% and 4.11% at 6 months and by 4.84% and 3.26% at 12 months; cortical thickness significantly increased by 2.49% and 3.33% at 6 months and by 3.73% and 3.37% at 12 months; and buckling ratio significantly decreased by 2.97% and 2.57% at 6 months and by 3.86% and 2.99% at 12 months. CONCLUSION: Combined use of ibandronate and Eldecalcitol for 6 months significantly improved bone strength of the proximal femur in postmenopausal Japanese women with osteoporosis.

Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.[Pubmed:28293779]

J Bone Miner Metab. 2018 Mar;36(2):221-228.

This study reveals the changes in bone mineral density (BMD), the turnover rate, and the balance [multiple of median formation/multiple of median resorption (MoMf/MoMr)] affected by the selection of different bone resorption inhibitors after 24-month daily teriparatide (20 microg/day) administration. The turnover rate was calculated as radical(MoMf(2) + MoMr(2)), where MoMf = bone-specific alkaline phosphatase (BAP) value/18.6 and MoMr = tartrate-resistant acid phosphatase 5b (TRACP-5b) value/463. One hundred and twenty-one osteoporotic women (mean age 82.4 years) were randomly administered minodronate (50 mg/28 days), raloxifene (60 mg/day), or Eldecalcitol (0.75 microg/day) after teriparatide discontinuation. BMD was measured at 0, 24, and 48 weeks; BAP values and TRACP-5b were measured at 0, 12, 24, 36, and 48 weeks after administration of bone resorption inhibitors. In the minodronate group, BMD increased significantly from week 0 to weeks 24 and 48. The turnover rate was significantly reduced at week 12, and remained so over the entire course in all three groups. The speed of change of turnover rate was greatest in the minodronate group. The balance in the minodronate group shifted significantly toward formation dominance at week 12 (to 0.97 from 0.87) and then again toward resorption dominance (to 0.84) at week 24. However, no further advancement in resorption dominance was observed until week 48. Conversely, the balance in the raloxifene and Eldecalcitol groups shifted toward resorption dominance gradually over the entire course. In conclusion, the BMD-increasing effect was greatest with minodronate administration and depends not only on the decrease in turnover rate but also on changes in balance after teriparatide discontinuation.

A vitamin D analogue, eldecalcitol, enhances expression of fast myosin heavy chain subtypes in differentiated C2C12 myoblasts.[Pubmed:28017710]

J Orthop Sci. 2017 Mar;22(2):345-350.

BACKGROUND: Several lines of evidence indicate that the active form of vitamin D has an anabolic effect on skeletal muscle. Eldecalcitol, an analogue of the active form of vitamin D, has the potential to increase bone density and decrease fracture risk. The objective of this study was to investigate the effect of Eldecalcitol in C2C12 myogenic cells. METHODS: C2C12 cells were grown to confluency and the culture medium was replaced with low-glucose DMEM containing 2% horse serum. Eldecalcitol was added at a concentration of 1, 10 or 100 nM. Gene expression profiles of vitamin D receptor (VDR), MyoD, IGF-1, neonatal myosin heavy chain (MHC), and the fast MHC subtypes Ia, IIa, IIb and IId/x were analyzed by quantitative RT-PCR. Protein expression of MHC subtypes was evaluated by western blotting and immunostaining. RESULTS: Eldecalcitol upregulated gene expression of VDR, MyoD and IGF-1. Incubation with Eldecalcitol in the absence of serum followed by the addition of serum after 1 h was associated with greater increases in the expression of these genes compared with co-incubation with Eldecalcitol and serum. Gene expression of MHC subtypes IIa, IIb and IId/x was significantly increased by Eldecalcitol. Protein expression of fast MHC subtypes was significantly increased by Eldecalcitol at 1 and 10 nM. CONCLUSION: Similar to the active form of vitamin D, Eldecalcitol had an anabolic effect on fast MHC subtypes. Taking into account its pharmacokinetic profile, Eldecalcitol is expected to be beneficial for the maintenance and improvement of muscle function in elderly individuals.

Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis.[Pubmed:27974229]

Biochem Biophys Res Commun. 2017 Jan 22;482(4):1430-1436.

Rapid increases in the number of elderly people have dramatically increased the number of female and male osteoporosis patients. Osteoporosis often causes bone fragility fractures, and males exhibit particularly poor prognosis after these fractures, indicating that control of osteoporosis is crucial to maintain quality of men's lives. However, osteoporosis therapies available for men have lagged behind advances available for women. Here, we show that three selective estrogen receptor modulators (SERMs), namely, raloxifene, bazedoxifene, and tamoxifen, plus the vitamin D analogue ED71, also called Eldecalcitol, completely block orchiectomy-induced, testosterone-depleted bone loss in male mice in vivo. Patients treated with hormone deprivation therapy for prostate cancer also exhibit male osteoporosis, and bone management is critical for these patients. Given that androgen replacement therapy is not an option for these patients, our results represent a novel approach potentially useful to control male osteoporosis.

Description

Eldecalcitol (ED-71) is an orally active analogue of active vitamin D used in the treatment of osteoporosis. Eldecalcitol (ED-71) possesses a strong inhibitory effect on bone resorption and causes a significant increase in bone mineral density.

Keywords:

Eldecalcitol,104121-92-8,ED-71; 1,25-dihydroxyvitamin D3,Natural Products,VD/VDR, buy Eldecalcitol , Eldecalcitol supplier , purchase Eldecalcitol , Eldecalcitol cost , Eldecalcitol manufacturer , order Eldecalcitol , high purity Eldecalcitol

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: